Free Stock & ETF Comparisons

Compare Amwell and Hims & Hers by telehealth visit volume, DTC subscription growth, GLP-1 weight loss medication revenue, insurance coverage partnerships, and which health tech stock is better positioned.

Compare One Medical (Amazon Health) and Teladoc Health by membership primary care hybrid model, BetterHelp mental health growth, ARPU, and which digital-physical healthcare model wins enterprise employer health budgets.

Compare STERIS and Danaher by hospital sterile reprocessing service revenue, biotech instrument replacement cycle, consumable annuity revenue, and which medtech/life science platform compounder is a better buy post-biotech slowdown.

Compare Intuitive Surgical and NovaCure by da Vinci surgical system installed base, Optune TTFields clinical expansion, recurring instrument revenue, gross margin, and which medical device company captures a unique clinical moat.

Compare iRhythm Technologies and Inspire Medical Systems by Zio patch wearable cardiac monitoring ARR, hypoglossal nerve stimulation implant growth, insurance coverage expansion, and which medtech niche device company scales faster.

Compare Omnicell and Veeva Systems by hospital pharmacy automation ARR, Veeva CRM replacement revenue, subscription model transition, and which healthcare software company has a more defensible enterprise position.

Compare Perrigo and Amgen by consumer OTC healthcare products (Aleve, Compeed), biosimilar revenue ramp, obesity drug pipeline (Amgen), and which pharma stock offers better risk-adjusted returns.

Compare Jazz Pharmaceuticals and Axsome Therapeutics by Xywav narcolepsy franchise, AXS-05 MDD/Alzheimer's agitation launch, pipeline risk, and which CNS specialty pharma has more durable revenue.

Compare DexCom and Tandem Diabetes Care by continuous glucose monitor market share, closed-loop insulin delivery integration, OTC CGM opportunity, Abbott competition, and which diabetes device company has a clearer growth path.

Compare Insulet (Omnipod) and Tandem Diabetes Care by tubeless vs tubed insulin pump design preference, Omnipod 5 AID market penetration, international expansion pace, and which insulin pump company has more runway.

Compare NovaCure and Beam Therapeutics by TTFields revenue in glioblastoma/NSCLC, base editing precision gene therapy pipeline, clinical data readouts, and which cancer-focused biotech/medtech is the better speculative bet.

Compare Community Health Systems and Tenet Healthcare by rural community hospital revenue cycle, ambulatory surgery center (USPI) expansion, debt load, payer mix, and which hospital operator has the more credible deleveraging path.

Compare Oscar Health and Alignment Healthcare by ACA individual marketplace growth, Medicare Advantage risk model, medical loss ratio trend, per-member-per-month margin, and which tech-enabled health insurance company scales to profitability first.

Compare iRhythm Technologies and Agios Pharmaceuticals by Zio wearable cardiac monitor revenue, Tibsovo/Pyrukynd rare disease franchise, cash position, and which small/mid-cap healthcare company is on a better profitability path.

Compare Agiliti and Halozyme Therapeutics by medical equipment lifecycle service revenue, ENHANZE subcutaneous delivery royalties, recurring revenue predictability, and which healthcare services company is the more defensive investment.

Compare Veeva Systems and Medidata (Dassault Systèmes) by CRM replacement revenue in pharma, clinical data management ARR, Vault R&D suite adoption, and which life sciences software platform has the deeper regulatory moat.

Compare Envista Holdings and Danaher by dental implant/aligners market share, bioprocess equipment demand (post-COVID), consumable revenue mix, and which Danaher spin-off/peer offers more upside as life science end markets recover.

Compare Hologic and Becton Dickinson by molecular diagnostics revenue sustainability post-COVID, surgical robot (Hologic Fluent) launch, BD Alaris infusion pump recall recovery, and which medtech delivers more consistent organic growth.

Compare ResMed and Philips by CPAP market share gains from Philips recall, AirSense connected device subscription ARR, Philips Sleep & Respiratory Care recovery timeline, and which sleep apnea device company is the better investment.

Compare Thermo Fisher Scientific and Agilent Technologies by bioproduction instrument and consumable revenue recovery, mass spectrometry market leadership, pharmaceutical and biotech customer capex cycle, and which instrument giant compounds better.

Compare Illumina and Pacific Biosciences by short-read sequencing market share, long-read sequencing clinical and research adoption, oncology liquid biopsy opportunity, and which genomics sequencing company leads the next decade.

Compare Natera and GRAIL by multi-cancer early detection test market development, Signatera MRD monitoring revenue, Galleri commercial launch progress, insurance coverage milestones, and which liquid biopsy company reaches profitability first.

Compare Guardant Health and Foundation Medicine by liquid biopsy Shield colorectal cancer screening launch, tissue comprehensive genomic profiling revenue, reimbursement breadth, and which comprehensive genomic testing approach wins clinician adoption.

Compare XLV and IHI by diversified healthcare vs concentrated medtech exposure, pharma/biotech vs device/diagnostics weighting, expense ratio, and which healthcare equity ETF is right for an investor's portfolio position.

Compare Biohaven and Protagonist Therapeutics by CGRP migraine pipeline post-Pfizer acquisition revenue, iron deficiency drug rusfertide commercial launch, and which mid-stage specialty biotech has more near-term catalyst value.

Compare Veeva Systems and IQVIA by pharmaceutical CRM subscription ARR, clinical trial data analytics revenue, Vault R&D suite upsell, OCE (Veeva CRM replacement), and which life sciences technology platform is the more durable long-term compounder.

Compare Charles River Laboratories and Medpace Holdings by drug discovery outsourcing revenue, small/mid biotech CRO demand, COVID normalisation, and which contract research organisation is better managed through a biotech funding cycle.

Compare PerkinElmer and Bio-Techne by newborn screening instrument revenue, flow cytometry reagent ARR, COVID diagnostic normalisation, and which life science tool company has more durable growth from oncology and proteomics research.

Compare Align Technology (Invisalign) and SmileDirectClub's (legacy) business model by orthodontist channel vs DTC telehealth dentistry, gross margin premium, iTero scanner ecosystem lock-in, and which clear aligner approach is more scalable.

Compare STERIS and 3M by hospital sterile reprocessing service recurring revenue, health care segment earnings after PFAS litigation spin-off, and which healthcare products company has more predictable mid-cycle earnings.

Compare Bristol-Myers Squibb and Eli Lilly by Revlimid/Eliquis LOE impact vs Mounjaro/Zepbound obesity revenue, pipeline M&A strategy, dividend yield, and which large pharma stock is better positioned for the next five years.

Compare AbbVie and Merck by Skyrizi/Rinvoq Humira succession vs Keytruda patent cliff exposure, HIV and oncology pipeline depth, dividend growth, and which pharma giant is better prepared for the next decade of patent expirations.

Compare Edwards Lifesciences and NovaCure by transcatheter aortic valve (TAVR) market penetration, TTFields cancer therapy label expansion, structural heart disease TAM, and which medical device company has the more durable growth runway.

Compare Hill-Rom (now Baxter Welch Allyn) and Becton Dickinson by smart patient monitoring equipment ARR, Alaris infusion pump FDA recall resolution, diagnostics recurring consumable revenue, and which medtech turnaround is further along.

Compare Revance Therapeutics and Avient Corporation by DaxibotulinumtoxinA (DAXI) botulinum toxin market launch vs Botox/Dysport competition, and specialty polymer revenue for sustainable packaging, to highlight two very different speculative vs value investment cases.

Compare eHealth and GoHealth by Medicare Advantage plan enrollment, member retention, marketing cost per approved member, CMS commission regulation risk, and which Medicare insurance marketplace is closer to sustainable unit economics.

Compare Amarin and Docgo by Vascepa cardiovascular drug revenue sustainability post-generic entry, mobile health clinic government contract revenue, and which healthcare micro-cap is the better risk/reward proposition.

Compare Progyny and ACM Research by employer fertility benefits ARR, semiconductor wafer cleaning equipment revenue in China, TAM expansion, and which small/mid-cap growth company has more predictable near-term revenue.

Compare STAAR Surgical and Beam Therapeutics by EVO implantable collamer lens revenue growth vs base editing gene therapy clinical data, profitability timeline, and which medical innovation company is more suitable for growth-at-a-reasonable-price investors.

Compare Cross Country Healthcare and AMN Healthcare by travel nurse placement revenue normalisation, workforce solutions technology ARR, and which healthcare staffing company is better positioned as hospital labor markets normalise post-pandemic.

Compare Bausch & Lomb and Omnicell by contact lens and ophthalmic surgery revenue, hospital pharmacy robot dispensing ARR, and which healthcare product/automation company offers better earnings visibility through 2026.

Compare Phathom Pharmaceuticals and Arrowhead Pharmaceuticals by vonoprazan acid-related disease launch, RNAi liver-targeted therapy pipeline breadth, partnership revenue, and which specialty biotech is closer to self-sustaining cash flow.

Compare Sarepta Therapeutics and Summit Therapeutics by Elevidys Duchenne gene therapy revenue, ivonescimab lung cancer partnership (Summit/Akeso), regulatory timeline, and which rare disease biotech has higher near-term catalyst value.

Compare RxSight and Amphora by light adjustable intraocular lens post-cataract revenue ramp, specialty drug delivery device market, and which niche medical device company is capturing a new surgical standard of care.

Compare Glaukos and Amedisys by iDose sustained-release glaucoma drug delivery ARR, home health visit reimbursement, hospice admission growth, and which specialty healthcare company has more durable recurring revenue.

Compare Procept BioRobotics and Silk Road Medical by AquaBeam BPH robotic surgery adoption, TCAR carotid stenting device procedure growth, and which small-cap medical device company builds the more defensible clinical procedure moat.

Compare TransMedics and Butterfly Network by Organ Care System transport device revenue, handheld ultrasound probe subscription model, and which breakthrough medical device platform is on a faster path to hospital standard of care.

Compare Stevanato Group and Envista Holdings by pharmaceutical glass vial/syringe revenue, dental implant and orthodontic equipment market share, and which healthcare supplier delivers more consistent mid-cycle organic growth.